Rendering

Component: (Network and Table)
Network
134 - Disclosure - INCOME TAXES (Tables)
(http://acurapharm.com/role/IncomeTaxesTables)
Table(Implied)
Slicers (applies to each fact value in each table cell)
Income Tax Disclosure [Abstract]Period [Axis]
2016-01-01 - 2016-12-31
Income Tax Disclosure [Abstract]
 
Provision for Income Taxes
The reconciliation between our provision for income taxes and the amounts computed by multiplying our loss before taxes by the U.S. statutory tax rate is as follows (in thousands):
 
 
 
December 31,
 
 
 
2016
 
2015
 
Benefit at U.S. statutory 34%  tax rate
 
$
(2,512)
 
$
(1,696)
 
State taxes (benefit), net of federal effect
 
 
49
 
 
41
 
Research and development tax credits
 
 
-
 
 
-
 
Share-based compensation
 
 
159
 
 
184
 
Other
 
 
2
 
 
11
 
Change in valuation allowance
 
 
2,302
 
 
1,460
 
Provision for income taxes
 
$
-
 
$
-
 
 
 
Components Of Deferred Tax Assets
As of December 31, 2016 we had federal research and development tax credits of approximately $1.2 million, which expire in the years 2024 through 2034. We also had approximately $0.2 million of Indiana state research and development tax credits, which will expire in 2017.
 
The components of our deferred tax assets are as follows:
 
 
 
December 31,
 
 
 
2016
 
2015
 
 
 
(in thousands)
 
Deferred tax assets:
 
 
 
 
 
 
 
Estimated future value of NOLs
 
 
 
 
 
 
 
 - Federal
 
$
47,192
 
$
52,772
 
 - State
 
 
2,135
 
 
2,050
 
Research and development tax credits
 
 
1,320
 
 
1,394
 
Share-based compensation
 
 
57
 
 
38
 
Other, net
 
 
332
 
 
368
 
Total deferred taxes
 
 
51,036
 
 
56,622
 
Valuation allowance
 
 
(51,036)
 
 
(56,622)
 
Net deferred tax assets
 
$
-
 
$
-